Clinical trials: Hepatobiliary Disorders
Hepatic Impairment
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal…
- Trial name
- NCT07428525
- Testing
- AMG 133
- Where
- 5 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Non-alcoholic Fatty Liver Disease
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
This study design to examine performance of trigonella foenum-graecum (TFG) in treatment of non-alcoholic fatty liver disease. Base on inclusion and exclusion criteria, 50 patients select and then randomize into intervention and…
- Trial name
- NCT02303314
- Testing
- Trigonella Foenum-graecum Seed Extract
- Where
- Iran
- Volunteers
- 35 people
- Sponsor
- Shiraz University of Medical Sciences
Liver Disease, Lymphoproliferative Disorders
Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant
Despite advances in medical and gene therapy, orthotopic liver transplantation remains the only definitive therapeutic option for children with end-stage liver disease.
- Trial name
- NCT00063648
- Testing
- EBV-specific autologous CTL
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cirrhosis, Liver, Portal Hypertension
3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or…
- Conditions
- Cirrhosis, Liver, Portal Hypertension, Advanced Chronic Liver Disease
- Trial name
- NCT05475015
- Testing
- 3D-MRE, HVPG
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shengjing Hospital
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Fatty Liver, Fatty Liver, Nonalcoholic
Quantification of Hepatic Steatosis With Different Ultrasound Frequency
The objective of this study is: (1) to compare the feasibility (technical successes rate and reliability) in measuring attenuation coefficient between two different frequencies (3MHz, 4MHz) of ultrasound beam; (2) to evaluate and…
- Conditions
- Fatty Liver, Fatty Liver, Nonalcoholic, Ultrasound
- Trial name
- NCT05855239
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Jong Keon Jang
Steatohepatitis, Nonalcoholic
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224
The purpose of this study is to assess the effect of multiple ION224 doses when administered by subcutaneous (SC) injection for 49 weeks (end of the treatment [EOT]) on non-alcoholic steatohepatitis (NASH) histologic improvement…
- Trial name
- NCT04932512
- Testing
- ION224
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease.
- Trial name
- MODIFY (NCT05209100)
- Testing
- Sigmoidoscopy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Different Exercises on Intrahepatic Lipid in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
This is a single-center, randomized, parallel controlled study to explore the effects of aerobic exercise, resistance exercise or aerobic combined resistance exercise on liver lipid in patients with MASLD, consisting of a 12-week…
- Trial name
- NCT06994871
- Testing
- Aerobic exercise, Resistance exercise, combined exercise
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver biochemistry tests in the world. The prevalence rate of NAFLD has been reported to be 30-40% in men and 15-20% in women, up to 70% of people with…
- Trial name
- NCT04059029
- Testing
- Bariatric surgery
- Volunteers
- 200 people
- Sponsor
- Taipei Medical University Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003557
- Testing
- dolastatin 10
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic…
- Trial name
- LYNX (NCT07270601)
- Testing
- Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- ContextVision AB
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
Cirrhosis, Muscle Cramp
Non-Pharmaceutical Intervention for Cirrhotic Cramps Reduction: The NICCles Trial
This clinical trial is evaluating the feasibility of using a non-pharmaceutical treatment to improve the symptoms and severity of muscle cramps in patients with cirrhosis.
- Conditions
- Cirrhosis, Muscle Cramp, Ascites
- Trial name
- NCT04650295
- Testing
- Household Remedy, Tap water
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Michigan
Autoimmune Pancreatitis Type 1, Autoimmune Pancreatitis Type 2
Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR)
The goal of this observational, retrospective study is to learn about cancer risk in autoimmune pancreatitis (AIP) patients. The main questions it aims to answer are: Do patients with AIP have higher incidence of cancer in…
- Trial name
- AiPPEAR (NCT06328101)
- Volunteers
- 1,000 people
- Sponsor
- University Medical Center Goettingen
Non-Alcoholic Fatty Liver Disease
Liver Health and Metabolic Function in People With Obesity
This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.
- Trial name
- NCT03701828
- Testing
- Weight loss surgery
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Non Alcoholic Steatohepatitis
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
Patients of NASH (Non Alcoholic Steatohepatitis) cirrhosis with current or prior histological evidence of steatosis or steatohepatitis admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who…
- Trial name
- NCT02721264
- Testing
- Fecal Microbiota Transplant, Standard Medical Treatment
- Where
- India
- Volunteers
- 112 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Pancreatic Exocrine Insufficiency
Screening for Pancreatic Exocrine Insufficieny in Metabolic Associated Fatty Liver Disease Patients
to investigate the frequency of PEI in MAFLD
- Trial name
- NCT05804409
- Testing
- FECAL ELASTASE
- Volunteers
- 70 people
- Sponsor
- Assiut University
Liver Transplant Rejection, Liver Transplant; Complications
Safety of DNP007 in Healthy Subjects
This clinical trial evaluated the safety, tolerability, pharmacokinetic properties, and immunogenicity of DNP007 when administered as a single dose.
- Conditions
- Liver Transplant Rejection, Liver Transplant; Complications, Steatohepatitis, Nonalcoholic
- Trial name
- NCT06400771
- Testing
- DNP007
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Nonalcoholic Steatohepatitis
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M…
- Trial name
- FORTUNA (NCT05809934)
- Testing
- AZD2693
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.